In vitro analysis of colistin-carbapenem combination activity against Acinetobacter spp infection

Authors

  • Micheline Soudeiha Rodolphe Merieux Laboratory, School of Pharmacy, Saint Joseph University, Beirut, Lebanon
  • E Salem Sokhn Biomedical sciences department, Faculty of Medicine and Medical Sciences, University of Balamand, Koura, Lebanon
  • Ziad Daoud Biomedical sciences department, Faculty of Medicine and Medical Sciences, University of Balamand, Koura, Lebanon
  • Dolla Sarkis Rodolphe Merieux Laboratory, School of Pharmacy, Saint Joseph University, Beirut, Lebanon

DOI:

https://doi.org/10.3855/jidc.10072

Keywords:

Acinetobacter spp, additive combination, ICII

Abstract

Introduction: Increasing carbapenem resistance in Acinetobacter spp calls for the appraisal of alternative strategies in Acinetobacter spp infection therapy. This study aims at evaluating colistin-carbapenem combination against Acinetobacter spp using the checkerboard, Etest, and time-kill methods.

Methodology: One hundred nonrepetitive Acinetobacter spp isolates were collected from patients admitted at the Saint-George-Hospital-University-Medical-Center over a one year period. The identification was performed using the API20NE and confirmed by the amplification of the blaOXA-51-like. Susceptibility to colistin, and carbapenems were determined using the Etest, microdilution methods and interpreted according to the CLSI, 2015. Detection of the carbapenemases was performed by PCR amplification method. Clonality was determined by the 3-Locus PCR-typing and ERIC-PCR methods. The synergistic potential of the combination was determined by calculating the Fractional-Inhibitory-Concentration-Index, which determines a synergistic, additive, indifferent or antagonistic effect.

Results: In our study (84%) of the isolates were carbapenem resistant. Only one strain showed resistance to colistin. (99%) and (77%) of the Acinetobacter spp isolates harbored blaOXA-51-like and blaOXA-23-like respectively. (86.2%) of the A.baumannii isolates pertained to the International Clone II. An additive effect of the colistin-carbapenem combination was determined using the 3 methods. A decrease of 2.6 and 2.8 folds in the MIC of colistin was showed in colistin-meropenem and colistin-imipenem, respectively (p < 0.001). The Colistin-meropenem showed better effects when compared to colistin-imipenem (p < 0.05). Only a few isolates showed a synergistic effect in the time-kill assay.

Conclusion: Our study showed that the decrease in the MIC of colistin following colistin-carbapenem combination might be a promising antimicrobial approach for treating carbapenem-resistant Acinetobacter spp.

Downloads

Published

2018-02-22

How to Cite

1.
Soudeiha M, Sokhn ES, Daoud Z, Sarkis D (2018) In vitro analysis of colistin-carbapenem combination activity against Acinetobacter spp infection. J Infect Dev Ctries 12:11S. doi: 10.3855/jidc.10072

Issue

Vol. 12 No. 02.1: February 2018 - SUPPLEMENT

Section

The Lebanese LSIDCM

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC